Pyrraline is one of the major Maillard compounds resulting from the reaction of glucose with amino compounds at slightly acidic pH. For in vivo studies, monoclonal pyrraline antibodies were raised after immunization of Balb/c mice with keyhole limpet hemocyamin-caproyl pyrraline conjugate. Of 660 hybridoma clones from one donor, 260 produced an antibody to the free hapten, two of which named Pyr-A and Pyr-B also cross-reacted with L-lysyl pyrraline. Using Pyr-B antibody and an ELISA, a gradual increase in pyrraline immunoreactivity was observed in serum albumin incubated with glucose or 3-deoxyglucosone. Plasma pyrraline levels increased fourfold (P < 0.001) in Sprague-Dawley rats upon induction of diabetes with streptozotocin and were twofold increased in randomly selected plasmas from diabetic humans. Highly specific pyrraline immunoreactivity was detected in sclerosed glomeruli from diabetic and old normal kidneys as well as in renal arteries with arteriolosclerosis and in perivascular and peritubular sclerosed extracellular matrix and basement membranes. The preferential localization of pyrraline immunoreactivity in the extracellular matrix strengthens the notion that the advanced glycosylation reaction may contribute to decreased turnover and thickening of the extracellular matrix in diabetes and aging. (J. Clin.
Introduction
Nonenzymatic glycosylation (glycation) and the advanced Maillard reaction have been proposed to play a role in the pathogenesis ofdiabetic complications and in the aging process by forming protein and DNA adducts and cross-links (1) . In the case of simple reducing sugars such as aldohexoses, the reaction has been shown in vivo to proceed via the formation of a relatively stable Amadori product (Fig. 1) .
Past the stage ofthe Amadori product the reaction becomes very complex due to the many pathways through which the Amadori product can undergo degradation. Despite this complexity, some progress has been achieved in recent years with structure elucidation of advanced glycosylation end products and Amadori fragmentation products formed in vivo. There is now unequivocal evidence for the formation of carboxyalkylated proteins during glucose incubation as well as for their presence in aging and diabetic human lens and skin (2, 3) . Furthermore, our laboratory has recently reported the presence of a fluorescent pentose-derived lysine-arginine protein cross-link named pentosidine in a variety of human tissues rich in extracellular matrix (4, 5) . Yet other investigators have found evidence for the presence of advanced glycosylation end products of unknown structure in rat and human tissues (6, 7) .
As part of our efforts to assess the presence of specific advanced glycosylation/Maillard end products in vivo, a few years ago we investigated the structure of the major products resulting from the reaction of glucose with a simple amine under physiological conditions (8, 9) . The major product extractable into organic solvents was 5-hydroxymethyl-neopentylpyrrole-2-carbaldehyde (neopentyl pyrraline) (8) , a compound previously identified in model systems by other Maillard reaction scientists (10, 11) . Its lability towards acid hydrolysis precluded direct isolation from protein and an immunological assay for its quantitation as a protein hapten was developed. Using rabbit antiserum to caproyl pyrraline immobilized onto poly-L-lysine, we were able to demonstrate that glucose, its Amadori product of lysine, and 3-deoxyglucosone were all precursors of protein-bound pyrraline (12) .
Although the polyclonal antibody was helpful for deciphering the mechanism of formation of pyrraline, high levels of nonspecific staining made it useless forthe assessment ofimmunoreactivity specific to pyrraline in tissue sections. To circumvent this problem, we developed monoclonal antibodies to immobilized caproyl pyrraline in mice. Below we describe their production, characterization, and ability to recognize glucoseand diabetes-modified molecules, and we provide the first immunohistochemical demonstration of advanced Maillard/glycosylation products in tissue sections from humans who died of diabetic complications or old age.
Methods
Chemical synthesis ofpyrraline derivatives. The syntheses of caproyl pyrraline, butyl, propyl, L-lysyl, and neopentyl pyrralines were previously described (12) .
Synthesis of3-deoxyglucosone (3-DG).' 3-DG was prepared essentially according to the method of Khadem as described before (13) .
Coupling of caproyl pyrraline onto keyhole limpet hemocyanin (KLH). Caproyl pyrraline was coupled onto KLH using the carbodiimide coupling reaction enhanced by N-hydroxysulfosuccinimide (14) . KLH (7.0 mg; Calbiochem Corp., La Jolla, CA; M, = 3,000,000 7,500,000) and caproyl pyrraline (7.4 (16) . Spleen cells from the immunized mouse were fused with mouse myeloma cells ofthe SP 2/0 cell line at the cell ratio of 5:1. The cells were cultured with Hypoxanthine-Aminopterin-thymidine-supplemented RPMI 1640 medium to obtain selective growth of hybrid cells in the 96-well tissue culture plates containing a "feeder" suspension ofnormal Balb/c mouse spleen cells. When colonies of cloned hybridomas became visible, culture supernatants were tested for the presence ofmonoclonal antibody against caproyl pyrraline by ELISA as described above. Positive clones were expanded and tested for cross-reactivity against L-lysyl pyrraline by ELISA. Two clones that were found to secrete antibody recognizing L-lysyl pyrraline were subcloned twice by limiting dilution method. The subcloned hybridoma cells were expanded by intraperitoneal injection into Balb/c mice that had been previously primed by intraperitoneal injection of 0.5 ml of 2,6,10,14-tetramethylpentadecane (pristane). Ascites fluid was collected after -10 d and purified with protein A-Sepharose column.
Incubation ofhuman serum albumin with glucose or 3-deoxyglucosone. Defatted human serum albumin (A-1887; Sigma) was dissolved in PBS at pH 5.4 and 7.4 at a concentration of 100 mg/ml as a stock solution. A solution with a glucose concentration of 0, 5, 50, and 500 mM, and a protein concentration of 50 mg/ml was prepared from 1 M glucose solution in PBS at pH 5.4 or 7.4 at the appropriate ratio. Similar solutions containing 0, 5, and 50 mM of 3-DG at pH 5.4 and 7.4 were prepared. The solutions were sterilized by filtration through 0.2-Mm pore membrane (Acrodisc 4182; Gelman Sciences Inc., Ann Arbor, MI) into sterile conical tubes and incubated at 370C in the dark. AliAdvanced Glycosylation in Diabetic Tissuesquots of 1 ml were withdrawn on day 0, 6, 12, 20, and 30 using a sterile pipette and stored at -800C until assayed. Before ELISA, samples were dialyzed at 4VC for 48 h three times against 3 liters of PBS (pH 7.4). After dialysis, all samples were equalized with PBS to a final protein concentration of24 mg/ml using the protein assay kit (Bio-Rad Laboratories, Richmond, CA).
Incubation ofe-amino caproic acid (ACA) with glucose. e-ACA was incubated with 5, 50, and 500 mM glucose solution. The final concentration of e-ACA was adjusted to 5.9 mg/ml in PBS (pH 5.4 and 7.4), such that the number ofe-amino groups per milliter solution was identical with that contained in 1 ml of 50 mg/ml HSA solution assuming 59 L-lysyl residues per mole HSA. The incubation was done under sterile conditions as described above. Aliquots were taken on day 0, 6, 12, 20, and 30 and frozen at -80'C until assayed for caproyl pyrraline by ELISA.
Ninhydrin treatment to lysylpyrraline. 200 ,g of40 mM lysyl pyrraline was treated with 100 ul 10 mM ninhydrin in ethylalcohol/acetic acid, pH 5.0, for 10 min at 650C. Alanine at a concentration of20 mM in PBS was then added and incubated for additional 10 min. The reaction mixture was evaporated to dryness and reconstituted in 200 ul PBS. ELISA was performed using 0.02-2,000 pmol deaminated lysyl pyrraline (i.e., "norlysyl pyrraline") as described above.
Preparation ofdiabetic rat plasma. 20 Sprague-Dawley female rats (200-220 g) were used for evaluation ofpyrraline formation in experimental diabetes. 12 rats were injected with streptozotocin (65 mg/kg body wt; The Upjohn Co., Kalamazoo, MI). Presence of diabetes was confirmed the next day by determination of glucosuria using Chemstrip 56 (Boehringer Mannheim Diagnostics, Inc.). Eight other rats were injected with 0.1 M citrate buffer (pH 4.5) as control. Blood was taken from the tail vein with heparinized syringe before and 2, 4, 7, 10, and 13 weeks after the injection. Plasma was separated by centrifugation (Microfuge; Beckman Instruments, Inc., Palo Alto, CA) and stored frozen until assayed. Plasma protein values were assessed using the protein assay kit (Bio-Rad) and adjusted to 5 mg/ml with PBS (pH 7.4) for pyrraline assay by ELISA. Red blood cells were processed for determination of glycohemoglobin by boronate affinity chromatography using the Glyco Gel B kit from Pierce Chemical Co.
Human plasma. 20 The color reaction was carried out by incubating the slide with freshly prepared 3,3-diaminobenzidine (DAB) reagent until staining was complete. This reagent was prepared by mixing 0.5 ml frozenthawed stock DAB reagent with freshly added 5 Ml of 30% H202 followed by 4.5 ml of 0.05 M TrisHCl, pH 7.6. The DAB stock reagent consists of 50 mg of DAB in 6.7 ml of Tris buffer. The reaction was stopped by placing the slide in water. Fixation was performed for 1 min in 0.5% OsO4 followed by a wash in water. The slides were counterstained with hematoxylin.
Results
Production ofantipyrraline antibodies in mice. The formation ofpyrraline antibodies in two mice that responded to the KLHimmunogen is shown in Fig. 2 . The titers were determined by ELISA and the mouse with the highest titer at 6 wk (mouse 1) was selected for the production of hybridomas. 260 clones out of 660 secreted antibody against the hapten caproyl pyrraline. All clones were further tested for their ability to recognize L-lysyl pyrraline. Two clones, 9A3 and lOCI 1, were found to crossreact with L-lysyl pyrraline and were therefore expanded. These clones were renamed Pyr-A and Pyr-B, respectively. Their antibodies were typed by immunodiffusion in agarose gels and found to belong to the class IgG 2a.
Pyr-A and Pyr-B clones were implanted into mouse peritoneum and purified antibodies were obtained after protein-A column chromatography as described above. Characterization ofmonoclonal Pyr-A and Pyr-B antibodies by ELISA. The details ofthe characterization ofPyr-A and Pyr-B are summarized in Table I . Reactivity with caproyl pyrraline, the free hapten, was defined as 100%. Both antibodies cross-reacted with higher affinity with butyl pyrraline than caproyl pyrraline (350% and 480%, respectively), suggesting that the absence of the carboxyl group in the free hapten increases the antibody affinity. On the contrary, the presence of the amino group in L-lysyl pyrraline decreased the cross-reactivity and 500 pmol/well was necessary to obtain 50% inhibition ofbinding in the case ofPyr-B (Fig. 3) . However, when the amino group of L-lysyl pyrraline was removed by ninhydrin treatment, the cross-reactivity of deaminated lysyl pyrraline (norlysyl pyrraline) increased from 0.24% to 15% (Fig. 3) . Further characterization of Pyr-A and Pyr-B revealed that Pyr-B was still able to recognize the sterically unfavorable neopentyl pyrraline, albeit at much higher concentrations. No cross-reactivity was seen with e-amino caproic acid, L-lysine, and e-fructosyl-L-lysine, suggesting that these residues in native proteins or tissue sections would not lead to nonspecific interactions. Furthermore, other unsubstituted pyrroles or end products of the Maillard reaction, such as neopentyl glycosyl pyrrole (9), were not recognized. The higher affinity of Pyr-B versus Pyr-A towards L-lysyl pyrraline led us to choose the former antibody for probing the advanced Maillard reaction in model systems and in proteins exposed to glucose in vitro and in vivo. Formation ofpyrraline in serum albumin and eamino caproic acid incubated with glucose and 3-deoxy-glucosone. Previous observations from our and other laboratories suggested that 3-DG is the immediate precursor to pyrraline and that the reaction is catalyzed at lower pH (12) . Overall similar results were obtained for human serum albumin incubated with 5 and 50 mM 3-DG in PBS (Fig. 4 , top and center panels). The levels ofpyrraline that were reached after 30 d ofincubation at 370C with 50 mM 3-DG were three times higher at pH 5.4 (i.e., 2,400 Figure 4 . Quantitation of pyrraline by ELISA in HSA incubated at 37°C in PBS with 3-deoxyglucosone and glucose at various pH and concentrations. The protein concentration was 50 mg/ml. The ELISA was standardized with L-lysyl pyrraline. Days Figure 5 . Quantitation of pyrraline in incubations of e-amino caproic with glucose under identical conditions as described in Fig. 4 . The concentration of e-amino caproic acid was adjusted to 45 mM to reflect the concentration of free e-amino groups of lysyl residues contained in 50 mg HSA/ml. The ELISA was standardized with caproyl pyrraline to allow comparison of absolute amounts.
pmol/mg HSA) than at pH 7.4 (i.e., 800 pmol/mg HSA) and 5-10 times lower at 5 mM 3-DG. The incubation of human serum albumin at pH 5.4 with glucose at three different concentrations revealed a lag period ofapproximately 10 days consistent with the necessity offorming Amadori products before 3-deoxyglucosone from which pyrraline is derived (Fig. 4, bottom panel) . When the reaction was carried out at pH 7.4, no HSA-bound pyrraline was detected (not shown). The reason why no pyrraline was detected at pH 7.4 and why a stronger relationship with glucose concentration was not observed at pH 5.4 appears to relate to the formation ofside products on the protein which mask the antigen accessibility. This was confirmed by incubating under identical conditions E-amino caproic acid with glucose using concentrations ofNH2-groups that were identical with those of HSA. Under these conditions, pyrraline formed at 500 mM glucose both at pH 5.4 and 7.4, and the overall pyrraline concentration at 30 d was in the same range as that observed at pH 5.4 with HSA (Fig. 5) . In a parallel experiment (not shown), we incubated Sepharose-lysine at 37°C with 500 mM glucose at pH 5.4 and 7.4 for a few days. At Weeks Figure 6 . Quantitation ofpyrraline immunoreactivity in plasma of diabetic rats and humans. Pyrraline immunoreactivity was quantitated in plasma from streptozotocin diabetic rats and from diabetic humans. After the onset of diabetes in rats, a rapid increase in the level of glycosylated hemoglobin was observed which plateaued at 4 wk (Fig. 6) . A slower but steady increase in pyrraline immunoreactivity developed in the plasma that reached plateau levels 3 wk later. This slow increase is compatible with the fact that glycated proteins are necessary precursors to pyrraline protein conjugates.
Rat plasma pyrraline immunoreactivity at 10 wk was compared with that of randomly obtained plasma specimens from diabetic individuals (Fig. 7) . Mean levels of glycohemoglobin in rat at that time was 13.7±2.0%, similar overall to that of the diabetic individuals (11.7±2.9%). However, whereas pyrraline immunoreactivity in nondiabetic rat and human plasma was overall similar (194.2±69.9 gM and 115.5±36.5 MM), mean pyrraline immunoreactivity was three times higher in diabetic rat plasma than in plasma from diabetic individuals (627.4±189.0 vs. 211.8±103.4 ,uM). Furthermore, whereas mean values were significantly elevated in diabetes (P < 0.001 and P < 0.01, respectively), definitive overlap between normal and diabetic values was present in human plasma, suggesting that the human is better protected against hyperglycemia than the rat at overall equivalent level of glycohemoglobin.
Immunocytochemicaldetection ofpyrraline immunoreactivity in tissue sections from diabetic subjects. Presence of pyrraline epitopes in relationship to diabetic complications and aging was sought in tissue sections obtained at autopsy from young, middle-aged, and old nondiabetic subjects, and in middle-aged subjects who died ofsevere complications. Representative findings frequently observed in age-and disease-matched subjects are presented below.
Almost no pyrraline immunoreactivity was observed in very young, i.e., 22-d old renal glomeruli or tubuli (Fig. 8 a) . However, pyrraline immunoreactivity was already apparent in adolescence and was associated with peritubular and extracellular matrix. The staining pattern was overall similar to that of a 36-yr old normal kidney (Fig. 7) . Glomerular and tubular structures were generally spared as long as these were free of sclerotic basement membranes. A frequent finding in diabetic kidneys with advanced Kimmelstiel-Wilson glomerulosclerosis was a crescent-shaped staining pattern which occasionally occupied the entire area ofterminally sclerosed glomeruli ( (Fig. 8 d) . Intense staining was also associated with thickened tubular extracelluhIt matrix. both in middle-aged diabetic and old nondiabetic kidney.
Particularly interesting findings were made in renal arteries from diabetic kidneys with severe arteriolosclerosis (Fig. 9 a) . Pyrraline immunoreactivity appeared to match precisely the contour ofthe sclerotic area (Fig. 9 a) . Intense staining was also present in the perivascular sclerotic matrix (Fig. 9 a) and in the arterial wall of an apparently healthy mid-size artery ofthe old kidney (Fig. 9 b) . The fact that the staining was highly specific for pyrraline is demonstrated by the ability ofthe free hapten to completely block binding ofthe monoclonal antibody and the subsequent staining by the secondary antibody (Fig. 9, c and  d) . The lowest free hapten (caproyl pyrraline) concentration at which complete blocking was obtained was 25 MM, i.e., the identical concentration used for complete inhibition in the ELISA.
Marked pyrraline immunoreactivity was also seen in thickened bronchial basement membrane from a diabetic lung (Fig.  10 a) and was diffusely present in collagenous tissue in trachea (Fig. 10 b) , skin (Fig. 10 c) , and pancreas (not shown). Basement membranes of brain microvessels were also positive for pyrraline (Fig. 10 d) . Age substantially these staining patterns. Overall, no major differences in pyrraline immunoreactivity were seen in coronary arteries, aortas, or nerves from middle-aged and elderly individuals with or without diabetes, although patchy pyrraline spots were occasionally seen in some aortas (not shown). Curiously, intense staining was observed in renal tubular cells from an infant who died after intravenous hyperalimentation (Fig.  10e) .
Discussion
The purpose ofthis study was The preferential formation of pyrraline in the extracellular matrix of renal and other tissues is not unexpected. Because overall pyrraline formation rate is slow, it is likely to be detected mainly in proteins with a slow turnover such as those of the extracellular matrix. This may also explain why the extracellular matrix ofyoung kidneys react to the pyrraline antibody with an overall staining pattern similar to that ofa middle-aged normal kidney. Thus, one can conclude that a certain degree of blockage of lysine residues by pyrraline may have little effect on the turnover ofthe extracellular matrix under physiological conditions. In contrast, the intense staining seen in thickened and sclerosed areas of diabetic and old kidneys suggests that pyrraline formation and sclerosis may be related processes.
A major question is how the focal formation ofpyrraline in sclerosed glomeruli and renal arteries should be interpreted. Obviously, ifthe advanced glycosylation reaction was only dependent on ambient glucose concentration, one would expect diffuse formation of pyrraline. However, a number of mechanisms may explain why the advanced Maillard reaction as reflected by pyrraline formation may not proceed in all tissue regions at the same rate. First, pyrraline-poor tissue regions may be metabolically more active than others, and enzymes like the 2-oxoreductase have been found to use 3-deoxyglucosone as substrate, thus preventing biochemical consequences of the advanced Maillard reaction such as cross-linking (17, 18) . Second, the turnover rate ofextracellular matrix poor in pyrraline may be higher due to focal differences in cellular composition. For example, it appears from Fig. 9, a and b , that cell density is generally lower in pyrraline-rich that in pyrralinepoor areas. Third, pyrraline-rich regions may result from the selective synthesis of extracellular matrix proteins that favor pyrraline synthesis or accessibility to the antibody. Work by a number of investigators suggests that hyperglycemia in diabetes may lead to increased synthesis of extracellular matrix proteins (19) . In the diabetic kidney, for example, synthesis of type IV collagen, laminin fibronectin is upregulated (20, 21) .
In arteriolosclerosis, on the other hand, there is a massive increase in extracellular matrix deposition as well as varying degree of hyalinization. Thus, some ofthese newly synthesized proteins could be preferential targets for the formation or detection ofantibody binding to a pyrraline epitope. Future studies using double-labelling technique may shed light on the question of whether pyrraline formation is specific to particular proteins of the extracellular matrix. In that regard, the increased affinity for deaminated lysyl-pyrraline, i.e., norlysylpyrraline (Fig. 3) suggests that the antibody may be recognizing an altered pyrraline structure in the tissue.
The unexpected finding of pyrraline immunoreactivity in tubular cells ofa kidney from an infant who died after a period of hyperalimention raises the question of whether this treatment modality catalyzes specifically the advanced Maillard reaction and whether tubular cells have reabsorbed pyrraline modified plasma proteins.
In summary, the availability of a monoclonal antibody to pyrraline revealed a strong association between sclerosis and pyrraline immunoreactivity in renal tissues from diabetic and aging individuals, providing further support to the concept that advanced glycosylation may decrease the reversibility of sclerotic lesions. However, at this point the question of whether pyrraline is simply an epiphenomenon or whether it has a direct pathogenetic role in the sclerotic process remains to be answered. Its ability to form cross-links by reacting with itself (22) would support the latter possibility.
